{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:45:49Z","timestamp":1789872349176,"version":"4.0.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Increased inflammation and oxidative stress may be caused by proteins and lipids modified by cytotoxic advanced glycation end products (AGEs) in food. Restricting food containing elevated AGEs improves these risk factors in diabetic CKD. Because diet adherence can be problematic, this study aimed to remove cytotoxic AGEs from food already ingested and to determine whether sevelamer carbonate sequesters cytotoxic AGEs in the gut, preventing their uptake and thereby reducing AGE-induced abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This single-center, randomized, 2-month, open-label, intention-to-treat, crossover study compared sevelamer carbonate with calcium carbonate treatment in stage 2\u20134 diabetic CKD. Participants received 2 months of treatment with one drug, had a 1-week washout, and then received the opposite drug for 2 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sevelamer carbonate reduced HbA1c, serum methylglyoxal, serum\n                      <jats:sup>\u03b5<\/jats:sup>\n                      N-carboxymethyl-lysine, triglycerides, and 8-isoprostanes. Total cholesterol and fibroblast growth factor 23 were reduced by sevelamer carbonate, relative to calcium carbonate. AGE receptor 1 and sirtuin 1 mRNA were increased and PMNC TNF\u03b1 levels were decreased by sevelamer carbonate, but not calcium carbonate. Medications and caloric and AGE intake remained unchanged. Sevelamer carbonate reversibly bound AGE-BSA at intestinal, but not stomach, pH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sevelamer carbonate significantly reduces HbA1c, fibroblast growth factor 23, lipids, and markers of inflammation and oxidative stress, and markedly increases antioxidant markers, independently of phosphorus in patients with diabetes and early kidney disease. These novel actions of sevelamer carbonate on metabolic and inflammatory abnormalities in type 2 diabetes mellitus may affect progression of early diabetic CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.12891211","type":"journal-article","created":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T01:46:05Z","timestamp":1333071965000},"page":"934-942","source":"Crossref","is-referenced-by-count":126,"title":["Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney Disease"],"prefix":"10.2215","volume":"7","author":[{"given":"Helen","family":"Vlassara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Uribarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pyzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Grosjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Striker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20230811","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2010040354","article-title":"Risk for ESRD in type 1 diabetes remains high despite renoprotection.","volume":"22","author":"Rosolowsky","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R2-10-20230811","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/dc09-0343","article-title":"Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline.","volume":"33","author":"Burrows","year":"2010","journal-title":"Diabetes Care"},{"key":"R5-10-20230811","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1152\/physrev.00014.2008","article-title":"Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species.","volume":"89","author":"Bashan","year":"2009","journal-title":"Physiol Rev"},{"key":"R6-10-20230811","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00394-010-0101-3","article-title":"Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1\u03b1 and MCP-1 levels in type 2 diabetic patients.","volume":"49","author":"Chao","year":"2010","journal-title":"Eur J Nutr"},{"key":"R7-10-20230811","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2337\/dc10-1675","article-title":"Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The Joslin 50-year medalist study.","volume":"34","author":"Sun","year":"2011","journal-title":"Diabetes Care"},{"key":"R8-10-20230811","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"R9-10-20230811","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy.","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R10-10-20230811","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc11-0091","article-title":"Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1.","volume":"34","author":"Uribarri","year":"2011","journal-title":"Diabetes Care"},{"key":"R11-10-20230811","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2353\/ajpath.2008.080152","article-title":"Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan.","volume":"173","author":"Cai","year":"2008","journal-title":"Am J Pathol"},{"key":"R12-10-20230811","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2337\/diabetes.52.9.2441","article-title":"Level of an advanced glycated end product is genetically determined: A study of normal twins.","volume":"52","author":"Leslie","year":"2003","journal-title":"Diabetes"},{"key":"R13-10-20230811","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"R14-10-20230811","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.","volume":"149","author":"Ferramosca","year":"2005","journal-title":"Am Heart J"},{"key":"R15-10-20230811","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.","volume":"57","author":"Kakuta","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R16-10-20230811","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2215\/CJN.05161107","article-title":"Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.","volume":"3","author":"Ketteler","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-10-20230811","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.04250510","article-title":"FGF-23 as a predictor of renal outcome in diabetic nephropathy.","volume":"6","author":"Titan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-10-20230811","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000111061","article-title":"Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.","volume":"28","author":"Shantouf","year":"2008","journal-title":"Am J Nephrol"},{"key":"R19-10-20230811","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.2215\/CJN.05880809","article-title":"Ten-year experience with sevelamer and calcium salts as phosphate binders.","volume":"5","author":"Raggi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-10-20230811","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease.","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R21-10-20230811","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney Int"},{"key":"R22-10-20230811","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R23-10-20230811","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jada.2004.05.214","article-title":"Advanced glycoxidation end products in commonly consumed foods.","volume":"104","author":"Goldberg","year":"2004","journal-title":"J Am Diet Assoc"},{"key":"R24-10-20230811","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","article-title":"Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy.","volume":"94","author":"Koschinsky","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-10-20230811","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/gerona\/62.4.427","article-title":"Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging.","volume":"62","author":"Uribarri","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R26-10-20230811","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2009-0089","article-title":"Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1.","volume":"94","author":"Vlassara","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-10-20230811","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1073\/pnas.0600362103","article-title":"Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor.","volume":"103","author":"Cai","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-10-20230811","doi-asserted-by":"crossref","first-page":"C145","DOI":"10.1152\/ajpcell.00350.2007","article-title":"AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation.","volume":"294","author":"Cai","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"R29-10-20230811","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0731-7085(02)00007-9","article-title":"Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.","volume":"29","author":"Swearingen","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"R30-10-20230811","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI119600","article-title":"Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.","volume":"100","author":"Mitsuhashi","year":"1997","journal-title":"J Clin Invest"},{"key":"R33-10-20230811","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2337\/diabetes.48.6.1308","article-title":"Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.","volume":"48","author":"He","year":"1999","journal-title":"Diabetes"},{"key":"R34-10-20230811","first-page":"2992","article-title":"Correlation of glucose regulation and hemoglobin A1C.","volume":"252","author":"Koenig","year":"1977","journal-title":"J Biochem"},{"key":"R35-10-20230811","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1001\/archinternmed.2011.351","article-title":"Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent.","volume":"171","author":"Paynter","year":"2011","journal-title":"Arch Intern Med"},{"key":"R36-10-20230811","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.168.18.1975","article-title":"Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects.","volume":"168","author":"Bays","year":"2008","journal-title":"Arch Intern Med"},{"key":"R37-10-20230811","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.amjcard.2011.06.011","article-title":"Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.","volume":"108","author":"Vega","year":"2011","journal-title":"Am J Cardiol"},{"key":"R38-10-20230811","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"R39-10-20230811","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA105.541854","article-title":"Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.","volume":"112","author":"Phan","year":"2005","journal-title":"Circulation"},{"key":"R40-10-20230811","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.1523-1755.2003.00284.x","article-title":"Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.","volume":"64","author":"Cozzolino","year":"2003","journal-title":"Kidney Int"},{"key":"R41-10-20230811","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: A systematic review and meta-analysis.","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R42-10-20230811","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/01.ASN.0000051593.41395.B9","article-title":"Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients.","volume":"14","author":"Uribarri","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R43-10-20230811","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/ATVBAHA.110.214619","article-title":"Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.","volume":"31","author":"Mirza","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R44-10-20230811","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0b013e318214b6b5","article-title":"Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients.","volume":"17","author":"Bili","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"R45-10-20230811","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000158483.13093.9D","article-title":"Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation.","volume":"111","author":"Dandona","year":"2005","journal-title":"Circulation"},{"key":"R46-10-20230811","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrcardio.2009.11","article-title":"Cardiovascular implications of proteinuria: an indicator of chronic kidney disease.","volume":"6","author":"Agrawal","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"R48-10-20230811","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","article-title":"Chronic kidney disease and the risk of end-stage renal disease versus death.","volume":"26","author":"Dalrymple","year":"2011","journal-title":"J Gen Intern Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201206000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:01Z","timestamp":1786369321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201206000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12891211","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}